[{"address1": "700 Saginaw Drive", "city": "Redwood City", "state": "CA", "zip": "94063", "country": "United States", "phone": "650 481 6801", "website": "https://www.revmed.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.", "fullTimeEmployees": 378, "companyOfficers": [{"maxAge": 1, "name": "Dr. Mark A. Goldsmith Ph.D.", "age": 61, "title": "CEO, President & Chairman", "yearBorn": 1962, "fiscalYear": 2022, "totalPay": 1053567, "exercisedValue": 470619, "unexercisedValue": 25079758}, {"maxAge": 1, "name": "Mr. Jack  Anders", "age": 46, "title": "Chief Financial Officer", "yearBorn": 1977, "fiscalYear": 2022, "totalPay": 544800, "exercisedValue": 0, "unexercisedValue": 1620884}, {"maxAge": 1, "name": "Ms. Margaret A. Horn J.D.", "age": 60, "title": "Chief Operating Officer", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": 775600, "exercisedValue": 0, "unexercisedValue": 7890083}, {"maxAge": 1, "name": "Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.", "age": 62, "title": "President of Research & Development", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": 779000, "exercisedValue": 0, "unexercisedValue": 4615888}, {"maxAge": 1, "name": "Ms. Xiaolin  Wang", "age": 52, "title": "Executive Vice President of Clinical Development", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": 604100, "exercisedValue": 0, "unexercisedValue": 4985429}, {"maxAge": 1, "name": "Dr. Martin D. Burke M.D., Ph.D.", "title": "Co-Founder & Chairman of Scientific Advisory Board", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael A. Fischbach Ph.D.", "age": 42, "title": "Academic Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1981, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kevan M. Shokat Ph.D.", "title": "Academic Co-Founder & Member of Scientific Advisory Board", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Walter  Reiher Ph.D.", "title": "Chief Information Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jan  Smith Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1711929600, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 34.92, "open": 35.31, "dayLow": 34.87, "dayHigh": 36.71, "regularMarketPreviousClose": 34.92, "regularMarketOpen": 35.31, "regularMarketDayLow": 34.87, "regularMarketDayHigh": 36.71, "beta": 1.539, "forwardPE": -10.620991, "volume": 897464, "regularMarketVolume": 897464, "averageVolume": 1456035, "averageVolume10days": 1723990, "averageDailyVolume10Day": 1723990, "bid": 36.41, "ask": 36.47, "bidSize": 400, "askSize": 400, "marketCap": 5999656960, "fiftyTwoWeekLow": 15.44, "fiftyTwoWeekHigh": 38.73, "priceToSalesTrailing12Months": 518.1051, "fiftyDayAverage": 31.8052, "twoHundredDayAverage": 28.282576, "currency": "USD", "enterpriseValue": 4234660608, "floatShares": 160843240, "sharesOutstanding": 164690000, "sharesShort": 12000365, "sharesShortPriorMonth": 17150136, "sharesShortPreviousMonthDate": 1709164800, "dateShortInterest": 1711584000, "sharesPercentSharesOut": 0.0729, "heldPercentInsiders": 0.02456, "heldPercentInstitutions": 0.96147, "shortRatio": 7.14, "shortPercentOfFloat": 0.0756, "bookValue": 11.09, "priceToBook": 3.2849414, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -436367008, "trailingEps": -3.86, "forwardEps": -3.43, "enterpriseToRevenue": 365.687, "enterpriseToEbitda": -9.273, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "RVMD", "underlyingSymbol": "RVMD", "shortName": "Revolution Medicines, Inc.", "longName": "Revolution Medicines, Inc.", "firstTradeDateEpochUtc": 1581604200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "2cb08d82-911b-38e3-94c5-2f2b3c1d7099", "gmtOffSetMilliseconds": -14400000, "currentPrice": 36.43, "targetHighPrice": 48.0, "targetLowPrice": 34.0, "targetMeanPrice": 41.58, "targetMedianPrice": 42.5, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 12, "totalCash": 1852955008, "totalCashPerShare": 11.251, "ebitda": -456675008, "totalDebt": 87944000, "quickRatio": 12.89, "currentRatio": 13.064, "totalRevenue": 11580000, "debtToEquity": 4.816, "revenuePerShare": 0.102, "returnOnAssets": -0.20083, "returnOnEquity": -0.34750998, "freeCashflow": -155203504, "operatingCashflow": -350572000, "revenueGrowth": -0.952, "operatingMargins": -208.1981, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-23"}]